WO2006015944A3 - Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof - Google Patents

Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof Download PDF

Info

Publication number
WO2006015944A3
WO2006015944A3 PCT/EP2005/053610 EP2005053610W WO2006015944A3 WO 2006015944 A3 WO2006015944 A3 WO 2006015944A3 EP 2005053610 W EP2005053610 W EP 2005053610W WO 2006015944 A3 WO2006015944 A3 WO 2006015944A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutically acceptable
acceptable salt
extended release
release tablet
tablet formulation
Prior art date
Application number
PCT/EP2005/053610
Other languages
French (fr)
Other versions
WO2006015944A2 (en
Inventor
Thomas Friedl
Wolfram Eisenreich
Original Assignee
Boehringer Ingelheim Int
Boehringer Ingelheim Pharma
Thomas Friedl
Wolfram Eisenreich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34926161&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2006015944(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to AU2005271194A priority Critical patent/AU2005271194B2/en
Priority to EA200700132A priority patent/EA016850B1/en
Priority to JP2007525280A priority patent/JP4785847B2/en
Priority to DK05763065.9T priority patent/DK1789021T4/en
Priority to MX2007001706A priority patent/MX2007001706A/en
Priority to PL05763065T priority patent/PL1789021T3/en
Priority to RS20110539A priority patent/RS52057B2/en
Priority to SI200531446T priority patent/SI1789021T1/en
Priority to AT05763065T priority patent/ATE532503T1/en
Priority to KR1020077005863A priority patent/KR101406767B1/en
Priority to EP05763065.9A priority patent/EP1789021B2/en
Priority to NZ553587A priority patent/NZ553587A/en
Priority to CN200580027635XA priority patent/CN101005831B/en
Priority to CA2572864A priority patent/CA2572864C/en
Priority to MEP-2011-195A priority patent/ME01316B/en
Priority to ES05763065T priority patent/ES2377214T3/en
Priority to BRPI0513846-9A priority patent/BRPI0513846A/en
Application filed by Boehringer Ingelheim Int, Boehringer Ingelheim Pharma, Thomas Friedl, Wolfram Eisenreich filed Critical Boehringer Ingelheim Int
Publication of WO2006015944A2 publication Critical patent/WO2006015944A2/en
Priority to NO20070719A priority patent/NO20070719L/en
Publication of WO2006015944A3 publication Critical patent/WO2006015944A3/en
Priority to IL181283A priority patent/IL181283A/en
Priority to HK07113428.8A priority patent/HK1104974A1/en
Priority to HRP20120068TT priority patent/HRP20120068T4/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Abstract

The invention is directed to an extended release tablet formulation comprising pramipexole or a pharmaceutically acceptable salt thereof in a matrix, the matrix comprising at least two water swelling polymers, wherein one of said polymers is pregelatinized starch, and wherein another one of said polymers is an anionic polymer.
PCT/EP2005/053610 2004-08-13 2005-07-25 Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof WO2006015944A2 (en)

Priority Applications (21)

Application Number Priority Date Filing Date Title
EP05763065.9A EP1789021B2 (en) 2004-08-13 2005-07-25 Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
BRPI0513846-9A BRPI0513846A (en) 2004-08-13 2005-07-25 prolonged-release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method of manufacture thereof and use thereof
JP2007525280A JP4785847B2 (en) 2004-08-13 2005-07-25 Tablet formulation with extended release comprising pramipexole or a pharmaceutically acceptable salt thereof, process for its production and use thereof
DK05763065.9T DK1789021T4 (en) 2004-08-13 2005-07-25 Extended-release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
MX2007001706A MX2007001706A (en) 2004-08-13 2005-07-25 Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof.
PL05763065T PL1789021T3 (en) 2004-08-13 2005-07-25 Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
RS20110539A RS52057B2 (en) 2004-08-13 2005-07-25 Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
SI200531446T SI1789021T1 (en) 2004-08-13 2005-07-25 Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
AT05763065T ATE532503T1 (en) 2004-08-13 2005-07-25 EXTENDED RELEASE TABLET FORMULATION CONTAINING PRAMIPEXOLE OR A PHARMACEUTICALLY APPROVED SALT THEREOF
KR1020077005863A KR101406767B1 (en) 2004-08-13 2005-07-25 Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
NZ553587A NZ553587A (en) 2004-08-13 2005-07-25 Extended release tablet formulation containing pramipexole or a pharmacutically acceptable salt thereof
AU2005271194A AU2005271194B2 (en) 2004-08-13 2005-07-25 Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
MEP-2011-195A ME01316B (en) 2004-08-13 2005-07-25 Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
CA2572864A CA2572864C (en) 2004-08-13 2005-07-25 Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
CN200580027635XA CN101005831B (en) 2004-08-13 2005-07-25 Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
ES05763065T ES2377214T3 (en) 2004-08-13 2005-07-25 Formulation in extended-release tablets containing pramipexole or a pharmaceutically acceptable salt thereof
EA200700132A EA016850B1 (en) 2004-08-13 2005-07-25 Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
NO20070719A NO20070719L (en) 2004-08-13 2007-02-08 Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, process for its preparation and use thereof
IL181283A IL181283A (en) 2004-08-13 2007-02-12 Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof for preparing a medical composition for the treatment of parkinson's disease
HK07113428.8A HK1104974A1 (en) 2004-08-13 2007-12-10 Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
HRP20120068TT HRP20120068T4 (en) 2004-08-13 2012-01-23 Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04019248.6 2004-08-13
EP04019248 2004-08-13

Publications (2)

Publication Number Publication Date
WO2006015944A2 WO2006015944A2 (en) 2006-02-16
WO2006015944A3 true WO2006015944A3 (en) 2007-02-08

Family

ID=34926161

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/EP2005/053610 WO2006015944A2 (en) 2004-08-13 2005-07-25 Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
PCT/EP2005/053602 WO2006015942A1 (en) 2004-08-13 2005-07-25 Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/053602 WO2006015942A1 (en) 2004-08-13 2005-07-25 Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof

Country Status (32)

Country Link
US (6) US7695734B2 (en)
EP (6) EP1789021B2 (en)
JP (5) JP4785847B2 (en)
KR (2) KR101406767B1 (en)
CN (4) CN101005830B (en)
AR (1) AR050602A1 (en)
AT (2) ATE486588T1 (en)
AU (3) AU2005271192B2 (en)
BR (2) BRPI0513847A (en)
CA (3) CA2572864C (en)
CY (2) CY1111713T1 (en)
DE (1) DE602005024570D1 (en)
DK (2) DK1781260T4 (en)
EA (4) EA015335B1 (en)
EC (2) ECSP077242A (en)
ES (2) ES2355735T5 (en)
HK (2) HK1104973A1 (en)
HR (2) HRP20100682T4 (en)
IL (3) IL181283A (en)
ME (2) ME01316B (en)
MX (2) MX2007001706A (en)
NO (2) NO342453B1 (en)
NZ (3) NZ553587A (en)
PL (2) PL1781260T5 (en)
PT (2) PT1781260E (en)
RS (2) RS51527B2 (en)
SG (1) SG148996A1 (en)
SI (2) SI1781260T2 (en)
TW (2) TWI347199B (en)
UA (3) UA89052C2 (en)
WO (2) WO2006015944A2 (en)
ZA (2) ZA200700085B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8377977B2 (en) 2004-08-13 2013-02-19 Boehringer Ingelheim International Gmbh Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
US8715728B2 (en) 2004-08-13 2014-05-06 Boehringer Ingelheim International Gmbh Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020035107A1 (en) 2000-06-20 2002-03-21 Stefan Henke Highly concentrated stable meloxicam solutions
US20050226926A1 (en) 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
PA8578501A1 (en) * 2002-07-25 2005-02-04 Pharmacia Corp DOSAGE FORM ONCE A DAY OF PRAMIPEXOL
US8992980B2 (en) 2002-10-25 2015-03-31 Boehringer Ingelheim Vetmedica Gmbh Water-soluble meloxicam granules
EP1568369A1 (en) 2004-02-23 2005-08-31 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam for the treatment of respiratory diseases in pigs
ES2539969T3 (en) * 2004-08-25 2015-07-07 Essentialis, Inc. Pharmaceutical formulations of ATP potassium channel activators and uses thereof
JP2009514871A (en) * 2005-11-04 2009-04-09 イーストマン ケミカル カンパニー Carboxyalkylcellulose esters for sustained delivery of pharmaceutically active substances
WO2007090882A2 (en) * 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Pharmaceutical extended release compositions comprising pramipexole
JP2009526021A (en) * 2006-02-10 2009-07-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Formulation with controlled release
WO2007090883A1 (en) * 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Extended release formulation
US8518926B2 (en) 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
FR2900823B1 (en) * 2006-05-15 2009-02-13 Bioprojet Soc Civ Ile NEW FORM OF ADMINISTRATION OF RACECADOTRIL.
ATE537826T1 (en) * 2006-05-16 2012-01-15 Knopp Neurosciences Inc COMPOSITIONS OF R(+)- AND S(-)-PRAMIPEXOLE AND METHOD FOR THEIR USE
WO2008009664A2 (en) * 2006-07-19 2008-01-24 Boehringer Ingelheim International Gmbh Treatment of pain
WO2008023027A2 (en) * 2006-08-24 2008-02-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for preparing pramipexole dihydrochloride tablets with high storage stability
US20080254118A1 (en) * 2007-04-11 2008-10-16 Hans-Werner Wernersbach Process for preparing pramipexole dihydrochloride tablets
US8524695B2 (en) 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
US8519148B2 (en) 2007-03-14 2013-08-27 Knopp Neurosciences, Inc. Synthesis of chirally purified substituted benzothiazole diamines
US20080254117A1 (en) * 2007-04-10 2008-10-16 Noel Cotton Process for preparing pramipexole dihydrochloride tablets
US20100092554A1 (en) * 2007-04-24 2010-04-15 Boehringer Ingelheim International Gmbh Combination with an extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
EP2291178A4 (en) * 2008-06-09 2013-07-24 Supernus Pharmaceuticals Inc Controlled release formulations of pramipexole
US20110190356A1 (en) 2008-08-19 2011-08-04 Knopp Neurosciences Inc. Compositions and Methods of Using (R)- Pramipexole
US20100159001A1 (en) * 2008-12-19 2010-06-24 Cardinal John R Extended-Release Pharmaceutical Formulations
BRPI1010129A2 (en) * 2009-07-02 2017-01-31 Supernus Pharmaceuticals Inc method of treating parkinson's disease in a mammalian individual
WO2011086182A2 (en) 2010-01-18 2011-07-21 Synthon Bv Pramipexole extended release tablets
US20120059013A1 (en) * 2010-03-09 2012-03-08 Boehringer Ingelheim International Gmbh Method of treating early morning akinesia in subjects having parkinson's disease
TR201001862A1 (en) * 2010-03-11 2011-10-21 Sanovel �La� San.Ve T�C.A.�. Controlled release pramipexole formulations.
KR101406265B1 (en) * 2010-03-17 2014-06-12 영진약품공업주식회사 Pharmaceutical composition of Pramipexole with improved stability and method for preparing thereof
US20130209553A1 (en) 2010-04-15 2013-08-15 Cadila Healthcare Limited Extended release pharmaceutical compositions of pramipexole
EP2380560A1 (en) * 2010-04-22 2011-10-26 ratiopharm GmbH Matrix tablets containing pramipexol
US9795568B2 (en) 2010-05-05 2017-10-24 Boehringer Ingelheim Vetmedica Gmbh Low concentration meloxicam tablets
JP2013526601A (en) 2010-05-24 2013-06-24 ルピン・リミテッド Sustained release formulation of pramipexole
WO2013034173A1 (en) 2011-09-06 2013-03-14 Synthon Bv Pramipexole extended release tablets
KR101439635B1 (en) * 2011-11-01 2014-09-11 대원제약주식회사 Pharmaceutical composition containing entecavir having enhanced stability and preparation method thereof
CN102406626B (en) * 2011-12-02 2013-08-28 深圳海王药业有限公司 Pramipexole hydrochloride slow release tablet and preparation method thereof
US9512096B2 (en) 2011-12-22 2016-12-06 Knopp Biosciences, LLP Synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
EP2806861A1 (en) * 2012-01-23 2014-12-03 Ranbaxy Laboratories Limited In-situ multilayered tablet technology
CN102836137A (en) * 2012-09-21 2012-12-26 山东齐都药业有限公司 Pramipexole dihydrochloride slow-release tablet with high content uniformity and preparation method thereof
EP2732812A1 (en) 2012-11-15 2014-05-21 Aristo Pharma GmbH Pramipexole retard tablet formulation
CN104744400B (en) * 2012-11-22 2017-08-11 北京三泉医药技术有限公司 Tetrahydrobenzothiazderivative derivative for treating sacred disease
CN102988319B (en) * 2012-12-10 2014-10-08 成都欣捷高新技术开发有限公司 III crystal form pramipexole hydrochloride tablet and preparation method thereof
CN103040781B (en) * 2013-01-04 2014-07-16 杭州朱养心药业有限公司 Pramipexole dihydrochloride tablet composition and preparation method thereof
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
CN104161735A (en) * 2013-05-19 2014-11-26 成都康弘药业集团股份有限公司 Sustained-release preparation containing pramipexole hydrochloride and preparation method thereof
LT3019167T (en) 2013-07-12 2021-03-25 Knopp Biosciences Llc Treating elevated levels of eosinophils and/or basophils
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
WO2015023786A1 (en) 2013-08-13 2015-02-19 Knopp Biosciences Llc Compositions and methods for treating plasma cell disorders and b-cell prolymphocytic disorders
PL3033081T3 (en) 2013-08-13 2021-08-30 Knopp Biosciences Llc Compositions and methods for treating chronic urticaria
CN103520128B (en) * 2013-10-12 2018-08-21 石家庄杏林锐步医药科技股份有限公司 A kind of sustained-release tablet of Pramipexole, preparation method and its usage
CN105456216B (en) * 2014-08-18 2019-11-05 江苏神龙药业股份有限公司 Pramipexole hydrochloride slow release tablet composition and preparation method thereof
JP2016113441A (en) * 2014-10-27 2016-06-23 大原薬品工業株式会社 Tablet in which release containing pramipexole dihydrochloride monohydrate is extended
CN105796519A (en) * 2014-12-30 2016-07-27 浙江京新药业股份有限公司 Pramipexole dihydrochloride sustained-release tablet and preparation method thereof
CN104606162B (en) * 2015-01-07 2017-03-29 海南康虹医药科技开发有限公司 A kind of body of Pramipexole dihydrochloride slow releasing preparation and preparation method thereof
JP6366547B2 (en) * 2015-08-03 2018-08-01 大原薬品工業株式会社 Pramipexole formulation package with improved photostability
CN105380917B (en) * 2015-08-24 2019-01-15 江苏神华药业有限公司 A kind of body of Pramipexole dihydrochloride sustained release tablets and preparation method thereof
CN106983729B (en) * 2016-01-21 2021-02-26 北京北大维信生物科技有限公司 Pramipexole sustained release tablet and preparation method thereof
CN107951853B (en) * 2016-10-17 2022-04-08 海思科制药(眉山)有限公司 Pramipexole dihydrochloride sustained-release pharmaceutical composition and preparation method thereof
CN108785263B (en) * 2017-04-26 2021-06-29 江苏恒瑞医药股份有限公司 Solid pharmaceutical composition of pramipexole or pharmaceutical salt thereof and preparation method thereof
ES2947367T3 (en) * 2017-07-26 2023-08-07 Tgx Soft Chew Llc Non-starchy soft chew for veterinary applications
US11234961B2 (en) 2017-08-17 2022-02-01 Zi-Qiang Gu Pamoate salt of monoamine anti-Parkinson's agents, method of preparation and use thereof
CN114939112B (en) * 2017-12-28 2024-03-01 北京北大维信生物科技有限公司 Pramipexole sustained-release pharmaceutical composition, preparation method and application thereof
CN108159007B (en) * 2017-12-29 2021-04-16 成都百裕制药股份有限公司 Pramipexole dihydrochloride sustained-release preparation and preparation method thereof
US20210228488A1 (en) * 2018-04-27 2021-07-29 Rubicon Research Private Limited Extended release compositions and process for preparation
CN112704668B (en) * 2021-01-12 2022-09-30 石药集团中奇制药技术（石家庄）有限公司 Pramipexole dihydrochloride sustained-release composition
CN112716908A (en) * 2021-02-03 2021-04-30 上海雅本化学有限公司 Preparation process of pramipexole
CN113876729B (en) * 2021-11-11 2023-05-30 南通联亚药业股份有限公司 Pramipexole dihydrochloride sustained-release tablet and preparation method thereof
CN114869854A (en) * 2022-04-18 2022-08-09 华裕(无锡)制药有限公司 Pramipexole dihydrochloride sustained-release tablet with high bioequivalence and preparation method thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0895780A1 (en) * 1997-07-31 1999-02-10 L. Perrigo Company Extended release tablets particularly containing pseudoephedrine hydrochloride
US20020114831A1 (en) * 2000-12-15 2002-08-22 Inger Norden Pharmaceutical formulation
WO2004010999A1 (en) * 2002-07-25 2004-02-05 Pharmacia Corporation Pramipexole once-daily dosage form
WO2004010997A1 (en) * 2002-07-25 2004-02-05 Pharmacia Corporation Sustained-release tablet composition of pramipexole

Family Cites Families (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2887440A (en) * 1957-08-12 1959-05-19 Dow Chemical Co Enteric coating
US3065143A (en) * 1960-04-19 1962-11-20 Richardson Merrell Inc Sustained release tablet
NL128902C (en) * 1960-06-06
US3458622A (en) * 1967-04-07 1969-07-29 Squibb & Sons Inc Controlled release tablet
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
JPS58403B2 (en) * 1975-07-24 1983-01-06 武田薬品工業株式会社 L- Ascorbine Sanseizaino Seizouhou
US4140755A (en) * 1976-02-13 1979-02-20 Hoffmann-La Roche Inc. Sustained release tablet formulations
US4167558A (en) * 1976-02-13 1979-09-11 Hoffmann-La Roche Inc. Novel sustained release tablet formulations
CH649215A5 (en) 1981-04-29 1985-05-15 Hoffmann La Roche PHARMACEUTICAL PREPARATIONS.
SE8103843L (en) * 1981-06-18 1982-12-19 Astra Laekemedel Ab PHARMACEUTICAL MIXTURE
US4424235A (en) * 1981-09-14 1984-01-03 Hoffmann-La Roche Inc. Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
DE3572485D1 (en) * 1984-12-22 1989-09-28 Thomae Gmbh Dr K Tetrahydro-benzothiazoles, their production and their use as intermediates or drugs
US4738851A (en) * 1985-09-27 1988-04-19 University Of Iowa Research Foundation, Inc. Controlled release ophthalmic gel formulation
US4666612A (en) * 1986-03-17 1987-05-19 Kerr-Mcgee Chemical Corporation Method for recovering a wood preservative from waste sludges
US4772473A (en) * 1986-06-16 1988-09-20 Norwich Eaton Pharmaceuticals, Inc. Nitrofurantoin dosage form
US4709712A (en) * 1986-10-22 1987-12-01 Dermatalogical Products Of Texas Polycarboxylic acid polymer gels as protective agents
US4968508A (en) * 1987-02-27 1990-11-06 Eli Lilly And Company Sustained release matrix
US4789549A (en) * 1987-03-09 1988-12-06 Warner-Lambert Company Sustained release dosage forms
US4859470A (en) 1988-06-02 1989-08-22 Alza Corporation Dosage form for delivering diltiazem
GB8828020D0 (en) * 1988-12-01 1989-01-05 Unilever Plc Topical composition
US5026559A (en) * 1989-04-03 1991-06-25 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
US5007790A (en) * 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
CA2051697C (en) 1989-06-09 1996-10-08 Malcolm Wilson Moon Heterocyclic amines having central nervous system activity
US5273975A (en) * 1989-06-09 1993-12-28 The Upjohn Company Heterocyclic amines having central nervous system activity
FR2653337B1 (en) 1989-10-23 1992-02-07 Dow Corning Sa SUSTAINED RELEASE ELEMENT AND METHOD FOR MANUFACTURING THE SAME.
IE82916B1 (en) * 1990-11-02 2003-06-11 Elan Corp Plc Formulations and their use in the treatment of neurological diseases
JPH04234812A (en) 1990-03-16 1992-08-24 Yamanouchi Pharmaceut Co Ltd Granule for long-acting pharmaceutical preparation
GB9015822D0 (en) * 1990-07-18 1990-09-05 Beecham Group Plc Compositions
US5472712A (en) * 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5681585A (en) * 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5656296A (en) * 1992-04-29 1997-08-12 Warner-Lambert Company Dual control sustained release drug delivery systems and methods for preparing same
US5731338A (en) * 1992-07-02 1998-03-24 Oramed, Inc. Controlled release pilocarpine delivery system
KR100355130B1 (en) 1992-09-18 2003-01-30 야마노우치세이야쿠 가부시키가이샤 Hydrogel Sustained Release Tablet
DE4241013A1 (en) * 1992-12-05 1994-06-09 Boehringer Ingelheim Kg Use of 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazole as antidepressant drug
US5431920A (en) * 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
US5458887A (en) * 1994-03-02 1995-10-17 Andrx Pharmaceuticals, Inc. Controlled release tablet formulation
DE4432757A1 (en) * 1994-09-14 1996-03-21 Boehringer Mannheim Gmbh Pharmaceutical preparation containing metformin and process for its preparation
WO1997004752A1 (en) * 1995-07-26 1997-02-13 Duramed Pharmaceuticals, Inc. Pharmaceutical compositions of conjugated estrogens and methods for their use
US5846971A (en) * 1996-06-28 1998-12-08 Schering Corporation Oral antifungal composition
JPH1017497A (en) * 1996-07-02 1998-01-20 Takeda Chem Ind Ltd Sustained release pharmaceutical preparation and its production
GB9619074D0 (en) 1996-09-12 1996-10-23 Smithkline Beecham Plc Composition
ES2248908T7 (en) 1997-06-06 2014-11-24 Depomed, Inc. Dosage forms of drugs orally and gastric retention for continued release of highly soluble drugs
CN1256085C (en) 1997-07-01 2006-05-17 美国辉瑞有限公司 Sertraline salts and substained-release dosage forms of sertraline
PT1009387E (en) 1997-07-02 2006-08-31 Euro Celtique Sa STABILIZED CONTROLLED FREQUENCY FORMULATIONS OF TRAMADOL
CA2211778A1 (en) 1997-08-14 1999-02-14 Francois Carriere Preparation of pregelatinized high amylose starch and debranched starch useful as an excipient for controlled release of active agents
US7153845B2 (en) * 1998-08-25 2006-12-26 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US6624200B2 (en) * 1998-08-25 2003-09-23 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US6248358B1 (en) 1998-08-25 2001-06-19 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets and methods of making and using the same
DE69819748T2 (en) * 1997-09-12 2004-09-30 Columbia Laboratories (Bermuda) Ltd. MEDICINES FOR TREATING DYSMENORRHEA AND PREVIOUS BLIES
ATE248583T1 (en) 1997-09-29 2003-09-15 Nektar Therapeutics STABILIZED PREPARATIONS USABLE IN DOSAGE INHALERS
US6197339B1 (en) 1997-09-30 2001-03-06 Pharmacia & Upjohn Company Sustained release tablet formulation to treat Parkinson's disease
US6056977A (en) * 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
US20020013304A1 (en) * 1997-10-28 2002-01-31 Wilson Leland F. As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness
US20020054911A1 (en) * 2000-05-11 2002-05-09 Boehringer Mannheim Pharmaceutical Corporation-Sm Ithkline Beckman Corporation, Limited Partnershi Novel oral dosage form for carvedilol
FR2772615B1 (en) * 1997-12-23 2002-06-14 Lipha MULTILAYER TABLET FOR INSTANT RELEASE THEN PROLONGED ACTIVE SUBSTANCES
GB9802201D0 (en) 1998-02-03 1998-04-01 Cerestar Holding Bv Free-flowable directly compressible starch as binder,disintegrant and filler for compresion tablets and hard gelatine capsules
PL342600A1 (en) 1998-03-11 2001-06-18 Smithkline Beecham Plc Composition
SG121745A1 (en) 1998-05-15 2006-05-26 Upjohn Co Cabergoline and pramipexole: new uses and combinations
GB9812426D0 (en) 1998-06-10 1998-08-05 Reckitt & Colmann Prod Ltd Improvements in or relating to organic compositions
US6312728B1 (en) 1998-07-07 2001-11-06 Cascade Development, Inc. Sustained release pharmaceutical preparation
TW407058B (en) * 1998-07-17 2000-10-01 Dev Center Biotechnology Oral cisapride dosage forms with an extended duration
US20010055613A1 (en) 1998-10-21 2001-12-27 Beth A. Burnside Oral pulsed dose drug delivery system
US6270805B1 (en) 1998-11-06 2001-08-07 Andrx Pharmaceuticals, Inc. Two pellet controlled release formulation for water soluble drugs which contains an alkaline metal stearate
DE19906290A1 (en) 1999-02-15 2000-08-17 Falk Pharma Gmbh Orally administered medicament for treating colon cancer comprises ursodesoxycholic acid in gastric fluid resistant coating to provide direct topical action at target site
MY121142A (en) * 1999-02-23 2005-12-30 Smithkline Beecham Corp Controlled release formulation for treating copd
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
ES2255490T3 (en) * 1999-03-31 2006-07-01 Janssen Pharmaceutica N.V. PREGELATINIZED ALMIDON IN A CONTROLLED RELEASE FORMULATION.
DE19927688A1 (en) * 1999-06-17 2000-12-21 Gruenenthal Gmbh Multi-layered tablet containing tramadole and diclofenac, useful for treating pain, has separating layer between active ingredient layers
HUP0201623A3 (en) 1999-07-01 2004-12-28 Upjohn Co Use of (s,s)reboxetine a selective norepinephrine reuptake inhibitor for the preparation of pharmaceutical compositions treating disorders of the nervous system
DE60042215D1 (en) * 1999-07-13 2009-06-25 Alpha Res Group Llc COMPOSITIONS AND METHODS OF TREATING PARKINSON DISEASE
WO2001010405A1 (en) 1999-08-04 2001-02-15 Ranbaxy Laboratories Limited Hydrodynamically balanced oral drug delivery system
CO5210862A1 (en) 1999-09-15 2002-10-30 Alza Corp DOSAGE FORMS AND METHODS TO PROVIDE REBOXETINE EFFECTIVE THERAPY WITH DOSAGE ONCE A DAY
GB9923045D0 (en) 1999-09-29 1999-12-01 Novartis Ag New oral formulations
WO2001022820A1 (en) 1999-09-30 2001-04-05 The General Hospital Corporation Use of pramipexole as a treatment for cocaine craving
MXPA02003976A (en) * 1999-10-19 2003-09-25 Nps Pharma Inc Sustained-release formulations for treating cns-mediated disorders.
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
WO2001045705A1 (en) * 1999-12-22 2001-06-28 Pharmacia Corporation Sustained-release formulation of a cyclooxygenase-2 inhibitor
US6467637B2 (en) * 2000-01-27 2002-10-22 The York Group, Inc. Death care merchandising system
PE20011074A1 (en) * 2000-02-23 2001-10-04 Upjohn Co USE OF PRAMIPEXOL IN THE TREATMENT OF ADDICTION DISORDERS
MXPA02008183A (en) * 2000-02-24 2002-11-29 Upjohn Co New drug combinations.
US6372252B1 (en) * 2000-04-28 2002-04-16 Adams Laboratories, Inc. Guaifenesin sustained release formulation and tablets
US6955821B2 (en) * 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
US6277875B1 (en) * 2000-07-17 2001-08-21 Andrew J. Holman Use of dopamine D2/D3 receptor agonists to treat fibromyalgia
JP2004505917A (en) * 2000-08-08 2004-02-26 テバ　ファーマシューティカル　インダストリーズ　リミティド Stable pergolide mesylate and method of making it
ES2187249B1 (en) 2000-09-18 2004-09-16 Synthon Bv PROCEDURE FOR THE PREPARATION OF 2-AMINO-6- (RENT) AMINO-4,5,6,7-TETRAHYDROBENZOTIAZOLES.
US6287599B1 (en) * 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
US20030022875A1 (en) * 2001-07-27 2003-01-30 Wilson Leland F. As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness
US20030032661A1 (en) * 2001-08-02 2003-02-13 Boehringer Ingelheim Pharma Kg Pramipexole as an anticonvulsant
DE10138275A1 (en) 2001-08-10 2003-02-27 Boehringer Ingelheim Pharma Connections to eliminate anhedonia
MXPA04006163A (en) 2001-12-20 2004-11-01 Pharmacia Corp Zero-order sustained released dosage forms and method of making the same.
DE60327843D1 (en) * 2002-03-04 2009-07-16 Ipsen Pharma MEDICAMENT FORMULATIONS WITH DELAYED RELEASE WITH A CARRIER PEPTIDE
ES2546010T3 (en) 2002-04-05 2015-09-17 Euro-Celtique S.A. Pharmaceutical preparation containing oxycodone and naloxone
MXPA04010225A (en) * 2002-04-15 2005-07-05 Adams Lab Inc Sustained release of guaifenesin combination drugs.
US20030215498A1 (en) * 2002-05-17 2003-11-20 Harland Ronald S. Rapidly disintegrating comressed tablets comprising biologically active compounds
AR040177A1 (en) * 2002-06-10 2005-03-16 Wyeth Corp O-DESMETIL-VENLAFAXINA FORMAT SALT
MXPA05000018A (en) 2002-06-27 2005-04-08 Cilag Ag Spherical pellet containing a water-soluble active ingredient.
JP4478413B2 (en) * 2002-07-11 2010-06-09 武田薬品工業株式会社 Manufacturing method of coated preparation
FR2842734A1 (en) * 2002-07-24 2004-01-30 Ethypharm Sa METHOD FOR DECREASING THE VARIABILITY OF THE BIOAVAILABILITY OF AN ORAL MEDICINAL PRODUCT AND ORAL PHARMACEUTICAL COMPOSITIONS
US20070196481A1 (en) * 2002-07-25 2007-08-23 Amidon Gregory E Sustained-release tablet composition
AU2003261223A1 (en) * 2002-07-25 2004-02-16 Pharmacia Corporation Method of preparing solid dosage forms coated in two layers comprising a water-insoluble polymer and a water-soluble pore former
US20040121010A1 (en) * 2002-10-25 2004-06-24 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
AU2003224467A1 (en) * 2003-03-11 2004-09-30 Korea United Pharm, Inc. Process for the preparing of hardcapsule formulation containing lansoprazole
WO2004087175A1 (en) 2003-04-04 2004-10-14 Pharmacia Corporation Oral extended release compressed tablets of multiparticulates
US20050020589A1 (en) * 2003-06-18 2005-01-27 Pfizer Inc. Sustained-release tablet composition comprising a dopamine receptor agonist
CN101849920A (en) * 2004-08-13 2010-10-06 贝林格尔·英格海姆国际有限公司 The prolongation that comprises pramipexole or its officinal salt discharges pellet formulation, Its Preparation Method And Use
RS51527B2 (en) * 2004-08-13 2018-02-28 Boehringer Ingelheim Int Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
WO2006046256A1 (en) 2004-10-27 2006-05-04 Alembic Limited Extended release formulation of pramipexole dihydrochloride
US20070148238A1 (en) 2005-06-23 2007-06-28 Spherics, Inc. Dosage forms for movement disorder treatment
CA2613107A1 (en) 2005-06-23 2007-01-04 Spherics, Inc. Delayed release or extended-delayed release dosage forms of pramipexole
AU2006279643B2 (en) 2005-08-15 2010-06-17 University Of Virginia Patent Foundation Neurorestoration with R(+) pramipexole
WO2007054976A2 (en) 2005-11-08 2007-05-18 Panacea Biotec Ltd. Lipid based controlled release pharmaceutical composition
WO2007090883A1 (en) 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Extended release formulation
WO2007090882A2 (en) 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Pharmaceutical extended release compositions comprising pramipexole
JP2009526021A (en) 2006-02-10 2009-07-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Formulation with controlled release
EP1886665A1 (en) 2006-08-01 2008-02-13 Boehringer Ingelheim Pharma GmbH & Co. KG Gastro retentive delivery system
CL2007002214A1 (en) * 2006-08-14 2008-03-07 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITION IN THE FORM OF COMPRESSED, WHERE AT LEAST THE LENGTH OF THE COMPRESSED IN THE PREVIOUS STATE OF THE APPLICATION IS AT LEAST 7/12 OF THE PILOR DIAMETER OF THE PATIENT AND AFTER INGERING IT IN THE FOOD STATE, THE LENGTH OF THE COMP
MX2009002031A (en) * 2006-08-25 2009-03-06 Boehringer Ingelheim Int Controlled release system and method for manufacturing the same.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0895780A1 (en) * 1997-07-31 1999-02-10 L. Perrigo Company Extended release tablets particularly containing pseudoephedrine hydrochloride
US20020114831A1 (en) * 2000-12-15 2002-08-22 Inger Norden Pharmaceutical formulation
WO2004010999A1 (en) * 2002-07-25 2004-02-05 Pharmacia Corporation Pramipexole once-daily dosage form
WO2004010997A1 (en) * 2002-07-25 2004-02-05 Pharmacia Corporation Sustained-release tablet composition of pramipexole

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SCHEIFE R T ET AL: "Impact of Parkinson's disease and its pharmacologic treatment on quality of life and economic outcomes.", AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY : AJHP : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS. 15 MAY 2000, vol. 57, no. 10, 15 May 2000 (2000-05-15), pages 953 - 962, XP008067655, ISSN: 1079-2082 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8377977B2 (en) 2004-08-13 2013-02-19 Boehringer Ingelheim International Gmbh Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
US8715728B2 (en) 2004-08-13 2014-05-06 Boehringer Ingelheim International Gmbh Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof

Also Published As

Publication number Publication date
EA200700132A1 (en) 2007-08-31
JP2008509194A (en) 2008-03-27
EA016850B1 (en) 2012-08-30
ES2355735T5 (en) 2014-06-27
EA200700201A1 (en) 2007-08-31
IL220313A0 (en) 2012-07-31
CA2572864A1 (en) 2006-02-16
CY1111713T1 (en) 2015-10-07
ECSP077242A (en) 2007-05-30
US20090182024A1 (en) 2009-07-16
ECSP077241A (en) 2007-03-29
NO20070719L (en) 2007-03-02
EP1781260B1 (en) 2010-11-03
SI1781260T2 (en) 2014-08-29
PL1781260T3 (en) 2011-04-29
CN101849921A (en) 2010-10-06
IL181283A (en) 2013-12-31
HRP20120068T4 (en) 2015-02-13
UA86831C2 (en) 2009-05-25
RS52057B2 (en) 2018-03-30
ATE532503T1 (en) 2011-11-15
US20090281153A1 (en) 2009-11-12
MX2007001706A (en) 2007-04-12
RS51527B (en) 2011-06-30
JP2008509192A (en) 2008-03-27
JP4785847B2 (en) 2011-10-05
DK1789021T3 (en) 2012-03-05
WO2006015942A1 (en) 2006-02-16
CA2736965A1 (en) 2006-02-16
EP2368545A1 (en) 2011-09-28
EA015335B1 (en) 2011-06-30
ZA200700085B (en) 2008-02-27
EP2286801A2 (en) 2011-02-23
NZ589267A (en) 2012-06-29
JP2011084577A (en) 2011-04-28
PL1781260T5 (en) 2014-09-30
DK1781260T4 (en) 2014-06-23
EA201001083A1 (en) 2011-08-30
HK1104974A1 (en) 2008-02-01
EP1789021B1 (en) 2011-11-09
HK1104973A1 (en) 2008-02-01
EP1789021B2 (en) 2014-10-08
NO342453B1 (en) 2018-05-22
BRPI0513846A (en) 2008-05-20
CN101005830B (en) 2010-09-29
SI1781260T1 (en) 2011-02-28
SG148996A1 (en) 2009-01-29
ES2355735T3 (en) 2011-03-30
NZ553587A (en) 2010-12-24
NO20070733L (en) 2007-03-06
TWI347850B (en) 2011-09-01
ME01316B (en) 2013-12-20
US20060051417A1 (en) 2006-03-09
AU2005271192A1 (en) 2006-02-16
PL1789021T3 (en) 2012-04-30
JP2011126916A (en) 2011-06-30
CN101005831A (en) 2007-07-25
RS52057B (en) 2012-04-30
HRP20100682T1 (en) 2011-01-31
MX2007001765A (en) 2007-04-20
CN101884626A (en) 2010-11-17
EP2135602A1 (en) 2009-12-23
JP4757872B2 (en) 2011-08-24
IL181282A0 (en) 2007-07-04
CN101005831B (en) 2010-11-10
BRPI0513847A (en) 2008-05-20
HRP20120068T1 (en) 2012-02-29
US7695734B2 (en) 2010-04-13
IL181282A (en) 2012-10-31
CY1112268T1 (en) 2015-12-09
DK1789021T4 (en) 2014-11-10
AR050602A1 (en) 2006-11-08
JP2009102409A (en) 2009-05-14
US20060198887A1 (en) 2006-09-07
AU2011250676A1 (en) 2011-12-01
ES2377214T3 (en) 2012-03-23
ATE486588T1 (en) 2010-11-15
KR101406767B1 (en) 2014-06-20
AU2005271194A1 (en) 2006-02-16
PT1789021E (en) 2011-12-22
AU2005271192B2 (en) 2011-11-17
DE602005024570D1 (en) 2010-12-16
TW200618821A (en) 2006-06-16
TW201100126A (en) 2011-01-01
TWI347199B (en) 2011-08-21
KR20070046172A (en) 2007-05-02
WO2006015944A2 (en) 2006-02-16
CA2572729A1 (en) 2006-02-16
UA89052C2 (en) 2009-12-25
HRP20100682T4 (en) 2014-08-01
CA2572864C (en) 2014-02-11
EA200900930A1 (en) 2009-12-30
EP1781260A1 (en) 2007-05-09
PT1781260E (en) 2010-12-20
IL181283A0 (en) 2007-07-04
EP2345407A1 (en) 2011-07-20
CN101005830A (en) 2007-07-25
ZA200700086B (en) 2008-02-27
US20130274300A1 (en) 2013-10-17
RS51527B2 (en) 2018-02-28
US20140335175A1 (en) 2014-11-13
KR20070052300A (en) 2007-05-21
EP1781260B9 (en) 2011-02-16
UA93608C2 (en) 2011-02-25
KR101052436B1 (en) 2011-07-29
EP1789021A2 (en) 2007-05-30
NZ553561A (en) 2010-12-24
CA2736965C (en) 2014-02-18
US8377977B2 (en) 2013-02-19
EP1781260B2 (en) 2014-04-02
AU2005271194B2 (en) 2011-11-24
DK1781260T3 (en) 2011-02-21
ME01442B (en) 2013-12-20
EP2286801A3 (en) 2012-05-09
CA2572729C (en) 2011-06-21
SI1789021T1 (en) 2012-02-29

Similar Documents

Publication Publication Date Title
WO2006015944A3 (en) Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
WO2008015220A8 (en) Granule and orally disintegrating tablet comprising oxycodone
GEP20074048B (en) Sustained-release tablet composition of pramipexole
USD603969S1 (en) Wrist orthosis
EA200870267A1 (en) SUSTAINABLE TO CREATING TABLETS INTENDED TO PREVENT ACCIDENTAL WRONG USE AND UNAUTHORIZED USE
WO2007040997A3 (en) Pharmaceutical dosage forms having immediate release and/or controlled release properties
WO2007010034A3 (en) Ampholytic copolymer, production thereof, and use of the same
TW200503786A (en) Fast dissolving orally consumable films containing a modified starch for improved heat and moisture resistance
WO2005118008A3 (en) Compositions and articles containing a crosslinked polymer matrix and an immobilized active liquid, as well as methods of making and using the same
WO2009006218A3 (en) Personal care dissolvable films
WO2003099985A3 (en) Tablet portions which can be dosed in a rinsing chamber
NO20026254L (en) Controlled Release Tablet, Controlled Release Excipient Preparation, and Cross-linked Hoyamylose Starch.
WO2001079347A3 (en) Polymer composition for pipes
WO2009001099A3 (en) A pharmaceutical composition comprising polyaphron dispersion
WO2007149804A3 (en) Lactam polymer derivatives
USD607114S1 (en) Adhesive knee brace
WO2009023761A3 (en) Pharmaceutical compositions comprising ropinirole
WO2009027786A3 (en) Matrix dosage forms of varenicline
WO2007143959A3 (en) Tablet containing metformin
WO2005105039A8 (en) Solid pharmaceutical form comprising an ltb4 antagonist
UY29105A1 (en) SOLID, SOLUBLE PHARMACEUTICAL COMPOSITION, FORMED BY AN ACTIVE PHARMACEUTICAL COMPOSITION AND A HYDROSOLUBLE POLYMERIC PHARMACEUTICAL COMPOSITION AND PREPRATION PROCEDURE
WO2004096155A3 (en) Tablets and methods for modified release of hydrophilic and other active agents
WO2007012859A3 (en) Denture support composition
WO2009004654A3 (en) Modified release dosage form of sulfonylurea compound
UA86868C2 (en) Prolonged release matrix tablet of glyclaside

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2005763065

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007/00085

Country of ref document: ZA

Ref document number: 200700085

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2572864

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 863/DELNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 07012642

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/001706

Country of ref document: MX

Ref document number: 2005271194

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 181283

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 200580027635.X

Country of ref document: CN

Ref document number: 12007500365

Country of ref document: PH

Ref document number: 2007525280

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 553587

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1200700498

Country of ref document: VN

ENP Entry into the national phase

Ref document number: 2005271194

Country of ref document: AU

Date of ref document: 20050725

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005271194

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020077005863

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 200700132

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 2005763065

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0513846

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: P-2011/0539

Country of ref document: RS